Bruker Reports Mixed FY25 Results, Projects Strong 15-17% Non-GAAP EPS Growth for FY26

summarizeSummary

Bruker Corporation reported mixed Q4 and full-year 2025 financial results, including a GAAP loss for the year, but provided optimistic FY26 guidance projecting 15-17% non-GAAP EPS growth and a return to organic revenue growth.

check_boxKey Events

• Q4 2025 Financial Performance

  Reported Q4-25 revenues of $977.2 million, flat year-over-year and down approximately 5% organically, with non-GAAP diluted EPS of $0.59, a decrease from the prior year.

• Full Year 2025 Challenges

  Full-year 2025 revenues reached $3.44 billion, up approximately 2% year-over-year but down approximately 4% organically. The company reported a GAAP diluted loss per share of $(0.15), impacted by $127.2 million in goodwill and intangible asset impairment charges and $77.4 million in restructuring charges.

• Positive FY26 Outlook

  Initiated FY26 guidance with expected revenues of $3.57 to $3.60 billion (4-5% year-over-year growth, 1-2% organic) and non-GAAP EPS of $2.10 to $2.15 (15-17% year-over-year growth), anticipating a return to organic revenue growth by Q2-26.

• Strategic Initiatives and Market Recovery

  Management highlighted ongoing cost-savings initiatives aimed at significant operating margin expansion and noted a book-to-bill ratio greater than 1.0x for the Scientific Instruments segment for the second consecutive quarter, indicating improving demand.

auto_awesomeAnalysis

This 8-K filing provides Bruker Corporation's full financial results for the fourth quarter and full year 2025, along with detailed guidance for fiscal year 2026. While 2025 was a challenging year, marked by a GAAP loss and a decline in non-GAAP EPS due to headwinds and significant charges, the company's forward-looking guidance is a key takeaway. The projection of 15-17% non-GAAP EPS growth and a return to organic revenue growth in 2026, coupled with ongoing cost-savings initiatives and a positive book-to-bill ratio in its Scientific Instruments segment, signals a potential turnaround. Investors will likely focus on the company's ability to execute on its 2026 targets and achieve the anticipated margin expansion and organic growth recovery.